Figure 3.

Polar plots of [¹⁸F]FDG-PET studies at 1–2 weeks and 6 months after placebo or BMC therapy. The patients are the same as in Figure 2. (A) The patient with placebo treatment has a large defect in the LAD region. The defect size is slightly reduced (34–27%) at 6 months, (B) a patient with BMC therapy has a moderate size defect in the LAD region at day 10–15 time-point, and the defect size was clearly reduced at 6 months follow-up (21–2%), and (C) a patient with BMC therapy has a moderate size defect in the LAD region and no clear change in the defect size (26–22%) was observed at 6 months follow-up.